GeminiBio Strengthens Board of Directors with Addition of Bryan Poltilove

Gemini BioProducts (GeminiBio), a portfolio company of BelHealth, a Florida-based healthcare private equity firm, and BroadOak Capital Partners, a life science-focused investment firm, has announced the appointment of Bryan Poltilove to the Board of Directors.

Mr. Poltilove is an operating partner at BroadOak Capital Partners and leads the firm’s investments in cell and gene therapy, bioproduction, and cell biology. Previously, Bryan spent 12 years with Thermo Fisher Scientific, where he served as Vice President and General Manager. Bryan grew the company’s cell-and-gene therapy business organically at 50%+ CAGR and through acquisitions, including Brammer Bio. Prior to Thermo Fisher, Bryan served as Director of Revenue Strategy & Operations at the Corporate Executive Board and held several commercial strategy roles with Johnson & Johnson. Bryan holds B.S. degrees in both Chemical Engineering and Economics from the Massachusetts Institute of Technology as well as an M.B.A. from the J.L. Kellogg School of Management at Northwestern University.

Brian Parker, CEO of GeminiBio added, “BroadOak has been a great partner and has supported GeminiBio as an investor with experience in our industry. Bryan’s deep knowledge of the cell and gene therapy sector will provide a meaningful perspective to our company. I very much look forward to working with him as a member of our Board of Directors.”

“I am excited to join the GeminiBio Board at such a pivotal time in the company’s evolution,” said Bryan Poltilove. “I look forward to working with the team to help execute on their growth plan.”